GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » 3-Year EBITDA Growth Rate

BIOYF (Biosyent) 3-Year EBITDA Growth Rate : 18.60% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent 3-Year EBITDA Growth Rate?

Biosyent's EBITDA per Share for the three months ended in Sep. 2024 was $0.19.

During the past 12 months, Biosyent's average EBITDA Per Share Growth Rate was 15.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 18.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 9.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biosyent was 213.50% per year. The lowest was -34.70% per year. And the median was 14.40% per year.


Competitive Comparison of Biosyent's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Biosyent's 3-Year EBITDA Growth Rate falls into.



Biosyent 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Biosyent  (OTCPK:BIOYF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Biosyent 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Biosyent's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.

Biosyent Headlines

From GuruFocus

BioSyent Declares Second Quarter 2023 Dividend

By GlobeNewswire GlobeNewswire 05-25-2023

Q3 2021 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2020 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

BioSyent to Attend Planet MicroCap Showcase

By GlobeNewswire 04-23-2024

Q2 2023 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q4 2021 Biosyent Inc Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

Q1 2019 Biosyent Inc Earnings Call Transcript

By GuruFocus Research 02-12-2024